Merck and a woman suing the drugmaker agreed to halt a trial over alleged injuries from the drugmaker's human papillomavirus ...

Deutsche Bank analyst James Shin downgraded Merck (MRK) to Hold from Buy with a price target of $105, down from $128. The firm believes the ...

(Reuters) -Merck and a woman suing the drugmaker agreed to halt a trial over alleged injuries from the drugmaker's human ...

Citi analyst Geoff Meacham maintained a Buy rating on Merck & Company (MRK – Research Report) today and set a price target of $115.00. The company’s shares closed yesterday at $90.74.

The company forecasts full-year 2025 adjusted EPS of $8.88 to $9.03, below the consensus estimate of $9.21. Revenue is projected to be between $64.1 billion and $65.6 billion, also lower than the ...

Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. However, when you're an income investor, your ...

Merck’s earnings estimates for 2025-2030 were lowered, with 2030 EPS now forecast to be significantly below 2024 levels. TD Cowen cut its price target on Merck from $121 to $100, citing weaker ...

Merck on Tuesday issued full-year 2025 revenue guidance that fell short of Wall Street's expectations. The company said that sales range reflects a decision to halt shipments of Gardasil ...